Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Chronic overload of SEPT4, a parkin substrate that aggregates in Parkinson's disease, causes behavioral alterations but not neurodegeneration in mice.

Ageta-Ishihara N, Yamakado H, Morita T, Hattori S, Takao K, Miyakawa T, Takahashi R, Kinoshita M.

Mol Brain. 2013 Aug 11;6:35. doi: 10.1186/1756-6606-6-35.

2.

Sept4, a component of presynaptic scaffold and Lewy bodies, is required for the suppression of alpha-synuclein neurotoxicity.

Ihara M, Yamasaki N, Hagiwara A, Tanigaki A, Kitano A, Hikawa R, Tomimoto H, Noda M, Takanashi M, Mori H, Hattori N, Miyakawa T, Kinoshita M.

Neuron. 2007 Feb 15;53(4):519-33.

3.

Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease.

Lo Bianco C, Schneider BL, Bauer M, Sajadi A, Brice A, Iwatsubo T, Aebischer P.

Proc Natl Acad Sci U S A. 2004 Dec 14;101(50):17510-5. Epub 2004 Dec 2.

4.

Inclusion body formation and neurodegeneration are parkin independent in a mouse model of alpha-synucleinopathy.

von Coelln R, Thomas B, Andrabi SA, Lim KL, Savitt JM, Saffary R, Stirling W, Bruno K, Hess EJ, Lee MK, Dawson VL, Dawson TM.

J Neurosci. 2006 Apr 5;26(14):3685-96.

5.

[Etiology and pathogenesis of Parkinson's disease: from mitochondrial dysfunctions to familial Parkinson's disease].

Hattori N.

Rinsho Shinkeigaku. 2004 Apr-May;44(4-5):241-62. Review. Japanese.

PMID:
15287506
6.

Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit age-dependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase K-resistant alpha-synuclein.

Lu XH, Fleming SM, Meurers B, Ackerson LC, Mortazavi F, Lo V, Hernandez D, Sulzer D, Jackson GR, Maidment NT, Chesselet MF, Yang XW.

J Neurosci. 2009 Feb 18;29(7):1962-76. doi: 10.1523/JNEUROSCI.5351-08.2009.

7.

Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease.

Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trockenbacher A, Schneider R, Mizuno Y, Kosik KS, Selkoe DJ.

Science. 2001 Jul 13;293(5528):263-9. Epub 2001 Jun 28.

8.

Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons.

Goldberg MS, Fleming SM, Palacino JJ, Cepeda C, Lam HA, Bhatnagar A, Meloni EG, Wu N, Ackerson LC, Klapstein GJ, Gajendiran M, Roth BL, Chesselet MF, Maidment NT, Levine MS, Shen J.

J Biol Chem. 2003 Oct 31;278(44):43628-35. Epub 2003 Aug 20.

9.

Expression of Lewy body protein septin 4 in postmortem brain of Parkinson's disease and control subjects.

Shehadeh L, Mitsi G, Adi N, Bishopric N, Papapetropoulos S.

Mov Disord. 2009 Jan 30;24(2):204-10. doi: 10.1002/mds.22306.

PMID:
18951507
10.

Septin 4, the drosophila ortholog of human CDCrel-1, accumulates in parkin mutant brains and is functionally related to the Nedd4 E3 ubiquitin ligase.

Muñoz-Soriano V, Nieto-Arellano R, Paricio N.

J Mol Neurosci. 2012 Sep;48(1):136-43. doi: 10.1007/s12031-012-9788-3. Epub 2012 May 6.

PMID:
22562816
11.

Effects of UCH-L1 on alpha-synuclein over-expression mouse model of Parkinson's disease.

Yasuda T, Nihira T, Ren YR, Cao XQ, Wada K, Setsuie R, Kabuta T, Wada K, Hattori N, Mizuno Y, Mochizuki H.

J Neurochem. 2009 Feb;108(4):932-44. doi: 10.1111/j.1471-4159.2008.05827.x. Epub 2009 Jan 7.

12.

Association of the cytoskeletal GTP-binding protein Sept4/H5 with cytoplasmic inclusions found in Parkinson's disease and other synucleinopathies.

Ihara M, Tomimoto H, Kitayama H, Morioka Y, Akiguchi I, Shibasaki H, Noda M, Kinoshita M.

J Biol Chem. 2003 Jun 27;278(26):24095-102. Epub 2003 Apr 14.

13.

Pael-R transgenic mice crossed with parkin deficient mice displayed progressive and selective catecholaminergic neuronal loss.

Wang HQ, Imai Y, Inoue H, Kataoka A, Iita S, Nukina N, Takahashi R.

J Neurochem. 2008 Oct;107(1):171-85. doi: 10.1111/j.1471-4159.2008.05607.x. Epub 2008 Aug 7.

14.

Parkin depletion delays motor decline dose-dependently without overtly affecting neuropathology in α-synuclein transgenic mice.

Fournier M, Roux A, Garrigue J, Muriel MP, Blanche P, Lashuel HA, Anderson JP, Barbour R, Huang J, du Montcel ST, Brice A, Corti O.

BMC Neurosci. 2013 Nov 5;14:135. doi: 10.1186/1471-2202-14-135.

15.

Parkin promotes degradation of the mitochondrial pro-apoptotic ARTS protein.

Kemeny S, Dery D, Loboda Y, Rovner M, Lev T, Zuri D, Finberg JP, Larisch S.

PLoS One. 2012;7(7):e38837. doi: 10.1371/journal.pone.0038837. Epub 2012 Jul 9.

16.
17.

Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein.

Koprich JB, Johnston TH, Huot P, Reyes MG, Espinosa M, Brotchie JM.

PLoS One. 2011 Mar 7;6(3):e17698. doi: 10.1371/journal.pone.0017698.

18.

The regulatory role of α-synuclein and parkin in neuronal cell apoptosis; possible implications for the pathogenesis of Parkinson's disease.

Yasuda T, Mochizuki H.

Apoptosis. 2010 Nov;15(11):1312-21. doi: 10.1007/s10495-010-0486-8. Review.

PMID:
20221696
19.

Ubiquitination increases parkin activity to promote autophagic α-synuclein clearance.

Lonskaya I, Desforges NM, Hebron ML, Moussa CE.

PLoS One. 2013 Dec 26;8(12):e83914. doi: 10.1371/journal.pone.0083914. eCollection 2013.

20.

Parkin-mediated protection of dopaminergic neurons in a chronic MPTP-minipump mouse model of Parkinson disease.

Yasuda T, Hayakawa H, Nihira T, Ren YR, Nakata Y, Nagai M, Hattori N, Miyake K, Takada M, Shimada T, Mizuno Y, Mochizuki H.

J Neuropathol Exp Neurol. 2011 Aug;70(8):686-97. doi: 10.1097/NEN.0b013e3182269ecd.

Items per page

Supplemental Content

Write to the Help Desk